01 January 2008
New insight of immunosuppressive drugs related nephrotoxicity
E. ThervetAnn Transplant 2008; 13(1): 10-10 :: ID: 880165
Abstract
Even though the incidence of acute rejection episode has been dramatically lowered after organ transplantation, long-term results have not improved consequently. Nephrotoxicity is a major side effect of the powerful immunosuppressive drugs used and may precluded long-term outcome. This side effect is well-recognized for calcineurine inhibitors but sirolimus (SRL), a mTOR inhibitor, also exhibit nephrotoxicity especially after delayed graft function. For calcineurine inhibitors, in vivo and in vitro data demonstrate that P-glycoproteine may play a critical role in protecting renal epithelial cells from cyclosporine A (CsA) toxicity. Regarding the molecular mechanisms, transcriptional profiles of human proximal tubular cells exposed to CsA found that it preferentially alters biological processes located at the cell membrane, such as ion transport or signal transduction. Wide expression analysis suggested that CsA may induce an endoplasmic reticulum (ER) stress in tubular cells in vitro and in vivo, because of cyclophilin A inhibition. Furthermore, CsA induces epithelial phenotypic changes reminiscent of an incomplete epithelial-to-mesenchymal transition in a TGF-b independent manner, as did various ER stress inducers. Finally, in primary cultured human tubular cells CsA induces autophagy dependant of ER stress. SRL modifies biological processes within the nucleus and related to transcriptional activity. It inhibits the proliferative response to mitogenic stimuli, and causes cell cycle arrest in the early G(1) phase, by a nonspecifi c process due to inhibition of the p70(S6k) pathway and by a direct effect on cyclin D3 mRNA stability. All these data demonstrate that new pathways have been defined recently to better understand the immunosuppressive drug associated nephrotoxicity giving possible clues to prevent this complication.
Keywords: Organ Transplantation, nephrotoxicity, carcinomatosis, intraperitoneal chemotherapy, cancer
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






